4 MEIP's, page-91

Any detailed research into Cantrixil, would have to strongly focus on what is happening with MEI Pharma and their drug ME344.

KZA have recently started referring to Cantrixil as a third generation drug. It would seem very apparent, that they are distinguishing between NOX and MEI and their respective, so far successful development of their "first" and "second" generation drugs. (Goes to show the pedigree and history of Cantrixil - this trial is far from a cross fingers and hope for the best).

Anyway MEI Pharma are extremely positive about ME344. That drug was also been endorsed by Dr Mor and his team at Yale in 2013 for ovarian cancer. (and I guess abdominal cancer in general)

http://www.meipharma.com/sites/default/files/Alvero_AACR_2013.pdf

MEI Pharma choose to do all their trails on breast cancer. Check out for yourself what they had to say in February.

Cantrixil is certainly a much more developed drug than ME344. So due to this good work undertaken by MEI Pharma, it would seem extremely likely our drug will be effective against breast cancer.

In certainly must always be in the minds of the respective CEO's at NOX and MEI Pharma, that their drugs appear to have been superseded by Cantrixil. Time will tell with this most interesting situation.

To some extend the MEI Pharma studies on ME344 have derisked the Cantrixil trial. (my view only - always do your own research and don't overextend your investment outlays)